Cost-of-Illness of Skin Cancer: A Systematic Review.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
accepted:
22
04
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
aheadofprint
Résumé
Skin cancer's rising incidence demands understanding of its economic impact. The current understanding is fragmented because of the various methodological approaches applied in skin cancer cost-of-illness studies. This study systematically reviews melanoma and keratinocyte carcinoma cost-of-illness studies to provide an overview of the applied methodological approaches and to identify the main cost drivers. This systematic review was conducted adhering to the 2020 PRISMA guidelines. PubMed, Embase, and Web of Science were searched from December 2022 until December 2023 using a search strategy with entry terms related to the concepts of skin cancer and cost of illness. The records were screened on the basis of the title and abstract and subsequently on full text against predetermined eligibility criteria. Articles published before 2012 were excluded. A nine-item checklist adapted for cost-of-illness studies was used to assess the methodological quality of the articles. This review included a total of 45 studies, together evaluating more than half a million patients. The majority of the studies (n = 36) focused on melanoma skin cancer, a few (n = 3) focused on keratinocyte carcinomas, and 6 studies examined both. Direct costs were estimated in all studies, while indirect costs were only estimated in nine studies. Considerable heterogeneity was observed across studies, mainly owing to disparities in study population, methodological approaches, included cost categories, and differences in healthcare systems. In melanoma skin cancer, both direct and indirect costs increased with progressing tumor stage. In advanced stage melanoma, systemic therapy emerged as the main cost driver. In contrast, for keratinocyte carcinoma no obvious cost drivers were identified. A homogeneous skin cancer cost-of-illness study design would be beneficial to enhance between-studies comparability, identification of cost drivers, and support evidence-based decision-making for skin cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Skin cancer's rising incidence demands understanding of its economic impact. The current understanding is fragmented because of the various methodological approaches applied in skin cancer cost-of-illness studies.
OBJECTIVE
OBJECTIVE
This study systematically reviews melanoma and keratinocyte carcinoma cost-of-illness studies to provide an overview of the applied methodological approaches and to identify the main cost drivers.
METHODS
METHODS
This systematic review was conducted adhering to the 2020 PRISMA guidelines. PubMed, Embase, and Web of Science were searched from December 2022 until December 2023 using a search strategy with entry terms related to the concepts of skin cancer and cost of illness. The records were screened on the basis of the title and abstract and subsequently on full text against predetermined eligibility criteria. Articles published before 2012 were excluded. A nine-item checklist adapted for cost-of-illness studies was used to assess the methodological quality of the articles.
RESULTS
RESULTS
This review included a total of 45 studies, together evaluating more than half a million patients. The majority of the studies (n = 36) focused on melanoma skin cancer, a few (n = 3) focused on keratinocyte carcinomas, and 6 studies examined both. Direct costs were estimated in all studies, while indirect costs were only estimated in nine studies. Considerable heterogeneity was observed across studies, mainly owing to disparities in study population, methodological approaches, included cost categories, and differences in healthcare systems. In melanoma skin cancer, both direct and indirect costs increased with progressing tumor stage. In advanced stage melanoma, systemic therapy emerged as the main cost driver. In contrast, for keratinocyte carcinoma no obvious cost drivers were identified.
CONCLUSIONS
CONCLUSIONS
A homogeneous skin cancer cost-of-illness study design would be beneficial to enhance between-studies comparability, identification of cost drivers, and support evidence-based decision-making for skin cancer.
Identifiants
pubmed: 38755518
doi: 10.1007/s40273-024-01389-5
pii: 10.1007/s40273-024-01389-5
doi:
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S69921N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : S006123N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 12Y2420N
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Urban K, Mehrmal S, Uppal P, Giesey RL, Delost GR. The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990–2017. JAAD Int. 2021;2:98–108.
pubmed: 34409358
pmcid: 8362234
doi: 10.1016/j.jdin.2020.10.013
Cancer Today [Internet]. [cited 2024 Feb 26]. Available from: https://gco.iarc.who.int/today/ .
Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer Oxf Engl. 1990;2023(192): 113254.
Brougham NDLS, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106:811–5.
pubmed: 22592943
doi: 10.1002/jso.23155
Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. Treatment-update 2023. Eur J Cancer Oxf Engl 1990. 2023;193:113252.
Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, et al. French updated recommendations in Stage I to III melanoma treatment and management. J Eur Acad Dermatol Venereol. 2017;31:594–602.
pubmed: 28120528
doi: 10.1111/jdv.14064
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment—update 2022. Eur J Cancer Oxf Engl 1990. 2022;170:256–84.
El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens—part D: radiation. Lancet Oncol. 2009;10:751–2.
pubmed: 19655431
doi: 10.1016/S1470-2045(09)70213-X
Krensel M, Schäfer I, Augustin M. Cost-of-illness of melanoma in Europe—a modelling approach. J Eur Acad Dermatol Venereol JEADV. 2019;33(Suppl 2):34–45.
pubmed: 30811699
doi: 10.1111/jdv.15308
Guy GPJ, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the US, 2002–2006 and 2007–2011. Am J Prev Med. 2015;48:183–7.
pubmed: 25442229
doi: 10.1016/j.amepre.2014.08.036
Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465–72.
pubmed: 36821107
pmcid: 9951101
doi: 10.1001/jamaoncol.2022.7826
Krensel M, Schäfer I, Augustin M. Modelling first-year cost-of-illness of melanoma attributable to sunbed use in Europe. J Eur Acad Dermatol Venereol JEADV. 2019;33(Suppl 2):46–56.
pubmed: 30811692
doi: 10.1111/jdv.15313
Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177–9.
pubmed: 11003181
pmcid: 1730654
doi: 10.1136/ip.6.3.177
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37.
pubmed: 25548737
pmcid: 4278062
doi: 10.3350/cmh.2014.20.4.327
Krensel M, Schäfer I, Augustin M. Cost-of-illness of melanoma in Europe—a systematic review of the published literature. J Eur Acad Dermatol Venereol JEADV. 2019;33:504–10.
pubmed: 30408246
doi: 10.1111/jdv.15315
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. Statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
Schirr-Bonnans S, Costa N, Derumeaux-Burel H, Bos J, Lepage B, Garnault V, et al. Cost of diabetic eye, renal and foot complications: a methodological review. Eur J Health Econ. 2017;18:293–312.
pubmed: 26975444
doi: 10.1007/s10198-016-0773-6
Tripathi R, Knusel KD, Ezaldein HH, Bordeaux JS, Scott JF. Characteristics of patients hospitalized for cutaneous squamous cell carcinoma. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2020;46:742–6.
Annemans L. Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations. New York: Academia Press; 2008.
Gordon LG, Leung W, Johns R, McNoe B, Lindsay D, Merollini KMD, et al. Estimated healthcare costs of melanoma and keratinocyte skin cancers in Australia and Aotearoa New Zealand in 2021. Int J Environ Res Public Health. 2022;19:3178.
pubmed: 35328865
pmcid: 8948716
doi: 10.3390/ijerph19063178
Doran CM, Ling R, Byrnes J, Crane M, Searles A, Perez D, et al. Estimating the economic costs of skin cancer in New South Wales, Australia. BMC Public Health. 2015;15:952.
pubmed: 26400024
pmcid: 4581089
doi: 10.1186/s12889-015-2267-3
Gordon LG, Elliott TM, Wright CY, Deghaye N, Visser W. Modelling the healthcare costs of skin cancer in South Africa. BMC Health Serv Res. 2016;16:113. https://doi.org/10.1186/s12913-016-1364-z .
Rowell D, Gordon LG, Olsen CM, Whiteman DC. A reconstruction of a medical history from administrative data: with an application to the cost of skin cancer. Health Econ Rev. 2015;5:4. https://doi.org/10.1186/s13561-015-0042-x .
Vallejo-Torres L, Morris S, Kinge JM, Poirier V, Verne J. Measuring current and future cost of skin cancer in England. J Public Health Oxf Engl. 2014;36:140–8.
doi: 10.1093/pubmed/fdt032
Bentzen J, Kjellberg J, Thorgaard C, Engholm G, Phillip A, Storm HH. Costs of illness for melanoma and nonmelanoma skin cancer in Denmark. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2013;22:569–76.
doi: 10.1097/CEJ.0b013e328360150c
Mofidi A, Tompa E, Spencer J, Kalcevich C, Peters CE, Kim J, et al. The economic burden of occupational non-melanoma skin cancer due to solar radiation. J Occup Environ Hyg. 2018;15:481–91.
pubmed: 29695213
doi: 10.1080/15459624.2018.1447118
Pil L, Hoorens I, Vossaert K, Kruse V, Tromme I, Speybroeck N, et al. Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. Prev Med. 2016;93:177–82.
pubmed: 27713103
doi: 10.1016/j.ypmed.2016.10.005
Buja A, Sartor G, Scioni M, Vecchiato A, Bolzan M, Rebba V, et al. Estimation of direct melanoma-related costs by disease stage and by phase of diagnosis and treatment according to clinical guidelines. Acta Derm Venereol. 2018;98:218–24.
pubmed: 29110018
doi: 10.2340/00015555-2830
Buja A, Rugge M, De Luca G, Zorzi M, De Toni C, Cozzolino C, et al. Malignant melanoma: direct costs by clinical and pathological profile. Dermatol Ther. 2022;12:1157–65.
doi: 10.1007/s13555-022-00715-z
da Veiga CRP, da Veiga CP, Souza A, Wainstein AJA, de Melo AC, Drummond-Lage AP. Cutaneous melanoma: cost of illness under Brazilian health system perspectives. BMC Health Serv Res. 2021;21:284.
pubmed: 33781270
pmcid: 8008665
doi: 10.1186/s12913-021-06246-1
Reyes C, DaCosta BS, Linke R, Satram-Hoang S, Teitelbaum AH. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. Melanoma Res. 2013;23:159–66.
pubmed: 23370422
doi: 10.1097/CMR.0b013e32835e58d6
Buja A, Cozzolino C, Zanovello A, Geppini R, Miatton A, Zorzi M, et al. Cost items in melanoma patients by clinical characteristics and time from diagnosis. Front Oncol. 2023;13:1234931.
pubmed: 38023154
pmcid: 10666743
doi: 10.3389/fonc.2023.1234931
Bateni SB, Nguyen P, Eskander A, Seung SJ, Mittmann N, Jalink M, et al. Changes in health care costs, survival, and time toxicity in the era of immunotherapy and targeted systemic therapy for melanoma. JAMA Dermatol. 2023;159:1195–204.
pubmed: 37672282
pmcid: 10483386
doi: 10.1001/jamadermatol.2023.3179
Crealey GE, Hackett C, Harkin K, Heckmann P, Kelleher F, Lyng Á, et al. Melanoma-related costs by disease stage and phase of management in Ireland. J Public Health Oxf Engl. 2023;45:714–22.
doi: 10.1093/pubmed/fdac154
Bencina G, Buljan M, Situm M, Stevanovic R, Benkovic V. Health and economic burden of skin melanoma in Croatia—cost-of-illness study. ACTA Dermatovenerol Croat. 2017;25:1–7.
pubmed: 28511743
Ignateva V, Derkach EV, Omelyanovsky V, Avxentyeva M. Economic burden of melanoma in Russia. Value Health. 2012;15:A417.
doi: 10.1016/j.jval.2012.08.1242
Watts C, Cust A, Menzies S, Coates E, Mann G, Morton R. Specialized surveillance for individuals at high risk for melanoma a cost analysis of a high-risk clinic. JAMA Dermatol. 2015;151:178–86.
pubmed: 25389712
doi: 10.1001/jamadermatol.2014.1952
Look Hong NJ, Cheng SY, Wright FC, Petrella TM, Earle CC, Mittmann N. Resource utilization and disaggregated cost analysis for initial treatment of melanoma. J Cancer Policy. 2018;16:63–9.
doi: 10.1016/j.jcpo.2018.04.006
Kapaki V, Kotsopoulos N, Constantopoulos A, Mathioudakis K, Souliotis K. The economic burden of cutaneous malignant melanoma in the Greek outpatient setting during the 3-year period, 2017–2019. Arch Hell Med. 2023;40:245–53.
McCarron CE, Zaric GS, Ernst DS. Costs and survival of patients with metastatic melanoma: evidence from the Ontario Cancer Registry and administrative databases. J Popul Ther Clin Pharmacol. 2014;21: e144.
de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KKW, Cheung WY, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16:809.
pubmed: 27756310
pmcid: 5070134
doi: 10.1186/s12885-016-2835-7
Chang C, Schabert V, Munakata J, Donga P, Abhyankar S, Reyes C, et al. Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Res. 2015;25:312–20.
pubmed: 25882026
doi: 10.1097/CMR.0000000000000159
Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin. 2015;31:1561–72.
pubmed: 26086578
doi: 10.1185/03007995.2015.1062356
Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, et al. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in the Netherlands. Anticancer Drugs. 2018;29:579–88.
pubmed: 29634490
doi: 10.1097/CAD.0000000000000628
Franken MG, Leeneman B, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, et al. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open. 2021;6: 100320.
pubmed: 34856511
pmcid: 8639434
doi: 10.1016/j.esmoop.2021.100320
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, et al. Update of survival and cost of metastatic melanoma with new drugs: estimations from the MelBase cohort. Eur J Cancer Oxf Engl. 1990;2018(105):33–40.
Potluri R, Ranjan S, Bhandari H, Johnson H, Moshyk A, Kotapati S. Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. Exp Hematol Oncol. 2019;8:14.
pubmed: 31312536
pmcid: 6610852
doi: 10.1186/s40164-019-0138-9
Klink AJ, Chmielowski B, Feinberg B, Ahsan S, Nero D, Liu FX. Health Care Resource Utilization and costs in first-line treatments for patients with metastatic melanoma in the United States. J Manag Care Spec Pharm. 2019;25:869–77.
pubmed: 30945965
Leeneman B, Uyl-de Groot CA, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, et al. Healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs. Cancers. 2020;12:1003.
pubmed: 32325748
pmcid: 7225943
doi: 10.3390/cancers12041003
van Boemmel-Wegmann S, Brown JD, Diaby V, Huo J, Silver N, Park H. Health care utilization and costs associated with systemic first-line metastatic melanoma therapies in the United States. JCO Oncol Pract. 2022;18:e163–74.
pubmed: 34228489
doi: 10.1200/OP.21.00140
Tawbi H, Bartley K, Seetasith A, Kent M, Lee J, Burton E, et al. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma. J Manag Care Spec Pharm. 2022;28:342–53.
pubmed: 35199578
Gautron Moura B, Gerard CL, Testart N, Caikovski M, Wicky A, Aedo-Lopez V, et al. Estimated costs of the ipilimumab-nivolumab therapy and related adverse events in metastatic melanoma. Cancers. 2022;15:31.
pubmed: 36612030
pmcid: 9817856
doi: 10.3390/cancers15010031
Soerensen AV, Kjellberg J, Ibsen R, Bastholt L, Schmidt H, Svane IM. Health care and socio-economic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma. Eur J Cancer. 2023. https://doi.org/10.1016/j.ejca.2023.113288 .
doi: 10.1016/j.ejca.2023.113288
pubmed: 37672816
Johnston K, Levy A, Lorigan P, Maio M, Lebbe C, Middleton M, et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). Eur J Cancer. 2012;48:2175–82.
pubmed: 22480965
doi: 10.1016/j.ejca.2012.03.003
Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, Guida M, Romanini A, Chiarion-Sileni V, Pigozzo J, Di Giacomo AM, Calandriello M, Didoni G, van Baardewijk M, Konto C, Lucioni C. The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res. 2012;31(1):91. https://doi.org/10.1186/1756-9966-31-91 .
Leeneman B, Blommestein HM, Coupé VMH, Hendriks MP, Kruit WHJ, Plaisier PW, et al. Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. Melanoma Res. 2021;31:249–57.
pubmed: 33871398
doi: 10.1097/CMR.0000000000000732
McArthur GA, Mohr P, Ascierto PA, Arance A, Banos Hernaez A, Kaskel P, et al. Health care resource utilization and associated costs among metastatic cutaneous melanoma patients treated with ipilimumab (INTUITION Study). Oncologist. 2017;22:951–62.
pubmed: 28526721
pmcid: 5553953
doi: 10.1634/theoncologist.2016-0272
Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2016;34:43–58.
pubmed: 26385101
doi: 10.1007/s40273-015-0325-4
Buja A, Rivera M, De Polo A, Zorzi M, Baracco M, Italiano I, et al. Differences in direct costs of patients with stage I cutaneous melanoma: a real-world data analysis. Eur J Surg Oncol. 2020;46:976–81.
pubmed: 32146052
doi: 10.1016/j.ejso.2020.02.017
Rüegg CP, Graf N, Mühleisen B, Szucs TD, French LE, Surber C, et al. Squamous cell carcinoma of the skin induces considerable sustained cost of care in organ transplant recipients. J Am Acad Dermatol. 2012;67:1242–9.
pubmed: 22695101
doi: 10.1016/j.jaad.2012.03.033
Jo M, Lee Y, Kim T. Medical care costs at the end of life among older adults with cancer: a national health insurance data-based cohort study. BMC Palliat Care. 2023;22:76.
pubmed: 37349710
pmcid: 10288735
doi: 10.1186/s12904-023-01197-2
Lee R, Mandala M, Long GV, Eggermont AMM, van Akkooi ACJ, Sandhu S, et al. Adjuvant therapy for stage II melanoma: the need for further studies. Eur J Cancer Oxf Engl. 1990;2023(189): 112914.
Hackshaw MD, Krishna A, Mauro DJ. Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery. Clin Outcomes Res. 2012;4:169–76.
doi: 10.2147/CEOR.S32349
Zhang Y, Le TK, Shaw JW, Kotapati S. Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma. Clin Outcomes Res. 2015;7:397–407.
Grange F, Mohr P, Harries M, Ehness R, Benjamin L, Siakpere O, et al. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Res. 2017;27:607–18.
pubmed: 28800027
doi: 10.1097/CMR.0000000000000372
Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, et al. Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Res. 2018;28:618–28.
pubmed: 30216199
pmcid: 6221390
doi: 10.1097/CMR.0000000000000507
Jang S, Poretta T, Bhagnani T, Harshaw Q, Burke M, Rao S. Real-world recurrence rates and economic burden in patients with resected early-stage melanoma. Dermatol Ther. 2020;10:985–99.
doi: 10.1007/s13555-020-00404-9